Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA CENTER FOR DRUGS DIRECTOR WOODCOCK TAKES OFFICE MAY 23

This article was originally published in The Tan Sheet

Executive Summary

FDA CENTER FOR DRUGS DIRECTOR WOODCOCK TAKES OFFICE MAY 23 following clearance by HHS to assume the top spot at the center from acting Director Murray Lumpkin, MD. The appointment of Janet Woodcock, MD to head the Center for Drug Evaluation and Research comes almost four months after FDA Commissioner David Kessler nominated her for the CDER director slot in late January ("The Tan Sheet" Jan. 31, p. 6). In the interim, she continued as director of the Office of Therapeutics Research & Review in the Center for Biologics Evaluation & Research. Lumpkin will resume his role as CDER deputy director for review management.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel